Indications |
Initial Treatment Strategy
(formerly Diagnosis and
Initial Staging) |
Subsequent Treatment Strategy (Includes Treatment Monitoring, Restaging and Detection of Suspected Recurrence) |
Male breast (175) |
C/NC23 |
C |
Kaposi's sarcoma (176) |
C |
NOPR |
Uterus, unspecified (179) |
C |
NOPR |
Cervix (180) |
C/NOPR4 |
C |
Uterus, body (182) |
C |
NOPR |
Placenta (181) |
C |
NOPR |
Ovary (183) |
C |
C |
Uterine adnexa (183.2-183.9) |
C |
NOPR |
Other and unspecified female genitalia (184) |
C |
NOPR |
Prostate (185) |
NC |
NOPR |
Testis (186) |
C |
NOPR |
| Penis and other male genitalia (187) |
C |
NOPR |
| Bladder (188) |
C |
NOPR |
| Kidney and other urinary tract (189) |
C |
NOPR |
| Eye (190) |
C |
NOPR |
| Primary brain (191) |
C |
NOPR |
| Other and unspecified nervous system (192) |
C |
NOPR |
| Thyroid (193) |
C |
C/NOPR5 |
| Other endocrine glands and related structures (194) |
C |
NOPR |
| Metastatic cancer / unknown primary organ (196-199) |
C |
NOPR |
| Lymphoma (200-202) |
C |
C |
| Myeloma (203) |
C |
C |
| Leukemia (204-208) |
NOPR |
NOPR |
| Neuroendocrine Tumor (209) |
C |
NOPR |
| Other or not listed |
C |
NOPR |
